JP2024514010A5 - - Google Patents
Info
- Publication number
- JP2024514010A5 JP2024514010A5 JP2023563854A JP2023563854A JP2024514010A5 JP 2024514010 A5 JP2024514010 A5 JP 2024514010A5 JP 2023563854 A JP2023563854 A JP 2023563854A JP 2023563854 A JP2023563854 A JP 2023563854A JP 2024514010 A5 JP2024514010 A5 JP 2024514010A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- cycloalkyl
- heterocyclyl
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024217755A JP2025028177A (ja) | 2021-04-21 | 2024-12-12 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177775P | 2021-04-21 | 2021-04-21 | |
| US63/177,775 | 2021-04-21 | ||
| US202163285410P | 2021-12-02 | 2021-12-02 | |
| US63/285,410 | 2021-12-02 | ||
| PCT/US2022/025329 WO2022225914A1 (en) | 2021-04-21 | 2022-04-19 | Carboxy-benzimidazole glp-1r modulating compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024217755A Division JP2025028177A (ja) | 2021-04-21 | 2024-12-12 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514010A JP2024514010A (ja) | 2024-03-27 |
| JP2024514010A5 true JP2024514010A5 (cg-RX-API-DMAC10.html) | 2024-04-24 |
| JP7642098B2 JP7642098B2 (ja) | 2025-03-07 |
Family
ID=81654849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563854A Active JP7642098B2 (ja) | 2021-04-21 | 2022-04-19 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
| JP2024217755A Pending JP2025028177A (ja) | 2021-04-21 | 2024-12-12 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024217755A Pending JP2025028177A (ja) | 2021-04-21 | 2024-12-12 | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Country Status (27)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| CN117098758A (zh) * | 2021-06-24 | 2023-11-21 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| EP4731245A1 (en) * | 2023-06-23 | 2026-04-29 | Merck Sharp & Dohme LLC | Use of a long-acting oxyntomodulin derivative for treament of fatty liver disease |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| TW202608914A (zh) * | 2024-04-23 | 2026-03-01 | 美商領導醫療公司 | 用於肥胖症及t2dm之人類glp1r及gipr之單促效劑及雙重促效劑化合物 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CR20220178A (es) * | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| KR102841983B1 (ko) * | 2019-11-04 | 2025-08-04 | 주식회사 엘지화학 | 광변조 디바이스의 제조 방법 |
| EP4069686B1 (en) * | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| CN116348464B (zh) * | 2020-10-12 | 2026-06-16 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
-
2022
- 2022-04-19 EP EP22723850.8A patent/EP4271674B9/en active Active
- 2022-04-19 CR CR20230493A patent/CR20230493A/es unknown
- 2022-04-19 SI SI202230115T patent/SI4271674T2/sl unknown
- 2022-04-19 MX MX2023012419A patent/MX2023012419A/es unknown
- 2022-04-19 KR KR1020267019234A patent/KR20260104194A/ko active Pending
- 2022-04-19 CA CA3216372A patent/CA3216372A1/en active Pending
- 2022-04-19 PH PH1/2023/552861A patent/PH12023552861A1/en unknown
- 2022-04-19 BR BR112023021978A patent/BR112023021978A2/pt unknown
- 2022-04-19 PT PT227238508T patent/PT4271674T/pt unknown
- 2022-04-19 HU HUE22723850A patent/HUE071198T2/hu unknown
- 2022-04-19 AU AU2022260487A patent/AU2022260487B2/en active Active
- 2022-04-19 PE PE2023002901A patent/PE20232051A1/es unknown
- 2022-04-19 US US17/723,758 patent/US20230021705A1/en not_active Abandoned
- 2022-04-19 DK DK22723850.8T patent/DK4271674T6/da active
- 2022-04-19 EP EP24218624.5A patent/EP4520393A3/en active Pending
- 2022-04-19 KR KR1020237040113A patent/KR102980213B1/ko active Active
- 2022-04-19 FI FIEP22723850.8T patent/FI4271674T6/fi active
- 2022-04-19 HR HRP20250415TT patent/HRP20250415T4/hr unknown
- 2022-04-19 UA UAA202305451A patent/UA130357C2/uk unknown
- 2022-04-19 PL PL22723850.8T patent/PL4271674T6/pl unknown
- 2022-04-19 JP JP2023563854A patent/JP7642098B2/ja active Active
- 2022-04-19 IL IL307768A patent/IL307768A/en unknown
- 2022-04-19 LT LTEPPCT/US2022/025329T patent/LT4271674T/lt unknown
- 2022-04-19 ES ES22723850T patent/ES3025032T7/es active Active
- 2022-04-19 WO PCT/US2022/025329 patent/WO2022225914A1/en not_active Ceased
- 2022-04-20 TW TW112137479A patent/TW202402752A/zh unknown
- 2022-04-20 TW TW111114937A patent/TWI819577B/zh active
-
2023
- 2023-10-19 DO DO2023000231A patent/DOP2023000231A/es unknown
- 2023-10-19 CL CL2023003113A patent/CL2023003113A1/es unknown
- 2023-10-19 CO CONC2023/0013766A patent/CO2023013766A2/es unknown
-
2024
- 2024-12-12 JP JP2024217755A patent/JP2025028177A/ja active Pending
-
2025
- 2025-03-20 US US19/085,239 patent/US20250312352A1/en active Pending
- 2025-05-12 DO DO2025000109A patent/DOP2025000109A/es unknown
- 2025-11-27 AU AU2025271403A patent/AU2025271403A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514009A5 (cg-RX-API-DMAC10.html) | ||
| HRP20250415T1 (hr) | Modulirajući spojevi karboksi-benzimidazola glp-1r | |
| CN115335374B (zh) | Glp-1r调节化合物 | |
| US10941113B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | |
| JP2023513272A5 (cg-RX-API-DMAC10.html) | ||
| ES2713566T3 (es) | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II | |
| JP2023540609A5 (cg-RX-API-DMAC10.html) | ||
| CN1195526C (zh) | 含对映体纯β-D-二氧戊环核苷的药物产品 | |
| JP6434416B2 (ja) | PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| JP2023515404A5 (cg-RX-API-DMAC10.html) | ||
| JP2019069940A (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
| US6525033B1 (en) | Nucleosides with anti-hepatitis B virus activity | |
| JP2021095409A (ja) | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 | |
| JP7769695B2 (ja) | Glp-1rアゴニストの結晶形態およびその使用 | |
| WO2018043747A1 (ja) | 抗b型肝炎ウイルス剤 | |
| KR20240068737A (ko) | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 | |
| US20160115149A1 (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2019517478A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2010027005A1 (ja) | 置換アミン誘導体及びこれを有効成分とする医薬組成物 | |
| JP2009102334A (ja) | 神経変性疾患治療剤 | |
| CN121985948A (zh) | Glp-1r激动剂的制剂及其制备方法 | |
| WO2011127388A2 (en) | Inverse agonists and neutral antagonists for the tsh receptor | |
| RU2470927C2 (ru) | Производные с азотсодержащим шестичленным ароматическим кольцом и содержащие их фармацевтические продукты | |
| TW201522291A (zh) | 胍基苯甲酸酯化合物 | |
| US6245817B1 (en) | NPY5 receptor antagonists and methods for using same |